This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants